# The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

> **NCT00518102** · — · COMPLETED · sponsor: **Ethicon, Inc.** · enrollment: 4431 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** REGRANEX (becaplermin)
- **OTHER:** REGRANEX (becaplermin) comparators

## Key facts

- **NCT ID:** NCT00518102
- **Lead sponsor:** Ethicon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 4431 (ACTUAL)
- **Last updated:** 2016-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518102, "The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00518102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*